Improved synergetic therapy efficiency of cryoablation and nanoparticles for MCF-7 breast cancer.
Current cryoablation therapy easily induces a high tumor recurrence, it is therefore necessary to develop an effective method to enhance its antitumor efficacy. We solve the aforementioned problem by introducing doxorubicin (DOX) loading methoxy polyethylene glycol-polylactic-co-glycolic acid-poly-L-lysine-cyclic arginine-glycine-aspartic acid peptide nanoparticles (DOX nanoparticles) in the process of cryoablation. The combination of cryoablation and DOX nanoparticles greatly decreases the recurrence rate of breast cancer, which is owing to the specific targeting therapy of DOX nanoparticles for residuary breast cancer cells after cryoablation. Therefore, the survival time of MCF-7 breast cancer bearing mice significantly increases. The synergetic therapy of cryoablation and DOX nanoparticles is an effective therapy means for breast cancer. This strategy provides new means for treating breast cancer.